Retraction
Combining PARP-1 Inhibition and Radiation in Ewing Sarcoma Results in Lethal DNA Damage
Paper Information
Record ID:
58520
Author(s):
Publication Date:
November 01, 2013
Retraction Date:
November 04, 2024
(1.0 year years ago)
Subjects:
Institutions:
- Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
- Division of Radiation Effects, Korea Institute of Radiological and Medical Sciences, Seoul, Korea
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, D.C.
- Departments of Pharmacology and Cancer Biology and Radiation Oncology, Duke University Medical Center, Durham, North Carolina
- Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York
Countries:
Article Type:
Publisher:
American Association for Cancer Research
Open Access:
Yes
PubMed ID:
Retraction PubMed ID:
Retraction Details
Retraction Reasons:
Nature of Retraction:
Retraction
Retraction Notice:
10.1158/1535-7163.MCT-24-0802Citations (82)
82
Total Citations5
Post-Retraction(6.1%)
76
Pre-Retraction1
Same DayPost-Retraction Citation Analysis
1
Within 30 days
5
Within 1 year
0
After 2+ years
226
Days since retraction (latest)
In Vitro and In Vivo Characterization of a Preclinical Irradiation-Adapted Model for Ewing Sarcoma
Mary C. Shapiro, Tien T. Tang, Atreyi Dasgupta et al. (7 authors)
International Journal of Radiation Oncology*Biology*Physics
Published: Feb 2018
7 citations
7 citations
2464 days before retraction
Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2
Britta Vormoor, Yvonne T. Schlosser, Helen Blair et al. (7 authors)
Oncotarget
Open Access
Published: Sep 2017
25 citations
25 citations
2594 days before retraction
Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies
Paul Lesueur, François Chevalier, Jean-Baptiste Austry et al. (9 authors)
Oncotarget
Open Access
Published: Jul 2017
120 citations
120 citations
2677 days before retraction
Advances in the Treatment of Pediatric Bone Sarcomas
Patrick J. Grohar, Katherine A. Janeway, Luke D. Mase et al. (4 authors)
American Society of Clinical Oncology Educational Book
Open Access
Published: May 2017
25 citations
25 citations
2744 days before retraction
PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models
Ymera Pignochino, Federica Capozzi, Lorenzo D’Ambrosio et al. (22 authors)
Molecular Cancer
Open Access
Published: Apr 2017
63 citations
63 citations
2747 days before retraction
The ETS family of oncogenic transcription factors in solid tumours
Gina M. Sizemore, Jason R. Pitarresi, Subhasree Balakrishnan et al. (4 authors)
Nature reviews. Cancer
Published: Apr 2017
309 citations
309 citations
2747 days before retraction
Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline <i>BRCA1/2</i> Mutations and Selected Sporadic Cancers
Johann S. de Bono, Ramesh K. Ramanathan, Lida A. Mina et al. (16 authors)
Cancer Discovery
Open Access
Published: Feb 2017
361 citations
361 citations
2806 days before retraction
Advances in the Treatment of Pediatric Bone Sarcomas
Patrick J. Grohar, Katherine A. Janeway, Luke D. Mase et al. (4 authors)
American Society of Clinical Oncology Educational Book
Open Access
Published: Jan 2017
21 citations
21 citations
2864 days before retraction
Potential approaches to the treatment of Ewing's sarcoma
Hongjiu Yu, Yonggui Ge, Lianying Guo et al. (4 authors)
Oncotarget
Open Access
Published: Oct 2016
45 citations
45 citations
2946 days before retraction
Expanding functions of ADP-ribosylation in the maintenance of genome integrity
Kathline Martin-Hernandez, José Manuel Rodríguez-Vargas, Valérie Schreiber et al. (4 authors)
Seminars in Cell and Developmental Biology
Published: Sep 2016
86 citations
86 citations
2963 days before retraction
An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma
Donna L. Nile, Colin Rae, Iain J. Hyndman et al. (5 authors)
BMC Cancer
Open Access
Published: Aug 2016
58 citations
58 citations
3007 days before retraction
Registered report: Systematic identification of genomic markers of drug sensitivity in cancer cells
John P. Vanden Heuvel, Jessica Bullenkamp
eLife
Open Access
Published: Jun 2016
5 citations
5 citations
3056 days before retraction
Investigational therapies for Ewing sarcoma: a search without a clear finding
Olga Vornicova, Gil Bar‐Sela
Expert Opinion on Investigational Drugs
Published: Mar 2016
13 citations
13 citations
3153 days before retraction
Integrative analysis for identifying joint modular patterns of gene-expression and drug-response data
Jinyu Chen, Shihua Zhang
Bioinformatics
Open Access
Published: Feb 2016
78 citations
78 citations
3199 days before retraction
Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway
Annemiek M. van Maldegem, Judith V.M.G. Bovée, Elleke F.P. Peterse et al. (5 authors)
European Journal of Cancer
Open Access
Published: Jan 2016
40 citations
40 citations
3230 days before retraction
Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer
Shih‐Hung Yang, Ting‐Chun Kuo, Hsu Wu et al. (10 authors)
World Journal of Gastroenterology
Open Access
Published: Jan 2016
29 citations
29 citations
3230 days before retraction
PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway
Florian Engert, Cornelius Schneider, Lilly Magdalena Weiβ et al. (5 authors)
Molecular Cancer Therapeutics
Open Access
Published: Oct 2015
58 citations
58 citations
3317 days before retraction
BRCA1 Mutation: A Predictive Marker for Radiation Therapy?
Charlene E. Kan, Junran Zhang
International Journal of Radiation Oncology*Biology*Physics
Open Access
Published: Sep 2015
52 citations
52 citations
3343 days before retraction
Liquid demixing of intrinsically disordered proteins is seeded by poly(ADP-ribose)
Matthias Altmeyer, Kai J. Neelsen, Federico Teloni et al. (11 authors)
Nature Communications
Open Access
Published: Aug 2015
551 citations
551 citations
3365 days before retraction
The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
José Luis Ordóñez, Ana Teresa Amaral, Ángel M. Carcaboso et al. (19 authors)
Oncotarget
Open Access
Published: May 2015
87 citations
87 citations
3449 days before retraction
Targeted therapies for advanced Ewing sarcoma family of tumors
Yunyun Jiang, Joseph A. Ludwig, Filip Janků
Cancer Treatment Reviews
Open Access
Published: Apr 2015
29 citations
29 citations
3495 days before retraction
Novel Therapies on the Horizon
Timothy P. Cripe, Kellie B. Haworth, Peter J. Houghton
Pediatric oncology
Published: Jan 2015
3595 days before retraction
EWS-FLI1 Regulates Genotoxic Stress Response in Ewing
Jason T. Yustein, Faris D. Virani Ewing
Unknown Journal
Published: Jan 2015
3595 days before retraction
RETRACTED: Inhibition of Vascular Endothelial Growth Factor A and Hypoxia-Inducible Factor 1α Maximizes the Effects of Radiation in Sarcoma Mouse Models Through Destruction of Tumor Vasculature
Hae‐June Lee, Changhwan Yoon, Do Joong Park et al. (12 authors)
International Journal of Radiation Oncology*Biology*Physics
Open Access
Published: Dec 2014
14 citations
14 citations
3603 days before retraction
Biochemical Properties and Biological Functions of FET Proteins
Jacob C. Schwartz, Thomas R. Cech, Roy Parker
Annual Review of Biochemistry
Open Access
Published: Dec 2014
208 citations
208 citations
3617 days before retraction
Targeting the DNA Repair Pathway in Ewing Sarcoma
Elizabeth Stewart, Ross Goshorn, Cori Bradley et al. (25 authors)
Cell Reports
Open Access
Published: Oct 2014
171 citations
171 citations
3664 days before retraction
Combining Targeted Agents With Modern Radiotherapy in Soft Tissue Sarcomas
Philip Wong, Peter J. Houghton, David G. Kirsch et al. (14 authors)
JNCI Journal of the National Cancer Institute
Open Access
Published: Oct 2014
32 citations
32 citations
3670 days before retraction
Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy
Heinrich Kovar
Expert Opinion on Therapeutic Targets
Published: Aug 2014
68 citations
68 citations
3722 days before retraction
Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma
Britta Vormoor, Nicola J. Curtin
Current Opinion in Oncology
Open Access
Published: May 2014
47 citations
47 citations
3821 days before retraction
The Pathogenesis of Ewing Sarcoma. Implications of Mesenchymal Stem Cells and New Therapeutic Strategies
Ana Teresa Monteiro Amaral
Unknown Journal
Open Access
Published: Jan 2014
3960 days before retraction
Targeted Radiosensitization of ETS Fusion-Positive Prostate Cancer through PARP1 Inhibition
Sumin Han, J. Chad Brenner, Aaron Sabolch et al. (10 authors)
Neoplasia
Open Access
Published: Oct 2013
52 citations
52 citations
4052 days before retraction
Molecular Mechanisms of PARP Inhibitors in BRCA-related Ovarian Cancer
Angela Toss
Journal of Cancer Science & Therapy
Open Access
Published: Jan 2013
24 citations
24 citations
4325 days before retraction
Quick Stats
Total Citations:
82
Years Since Retraction:
1.0 year
Open Access:
Yes
Last Checked:
Jul 24, 2025